Australian Prostate Cancer Research Centre - Queensland

Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development

Anja Rockstroh — 2024-04-28T00:00:00Z

This book chapter by Dr Philp et al aims to serve as a comprehensive resource for the preparation and adoption of PCa PDX models in the research laboratory and for their use as a valuable preclinical platform for translational research and therapeutic agent development.

Movember 2023 Fundraising Sale

Anja Rockstroh — 2023-11-29T00:00:00Z

Great team effort for our Movember 2023 Fundraising sale - making a difference in the community, in research and in peoples’ lives!

PAH Giving Day 2023 Bake Sale

Anja Rockstroh — 2023-09-07T00:00:00Z

Our amazing team has raised $2702 from our bake sale to support the Princess Alexandra Hospital Giving Day 2023.

Systematic review of antitumour efficacy and mechanism of metformin activity in prostate cancer models

Anja Rockstroh — 2022-09-30T00:00:00Z

Metformin, the first line pharmacotherapy for type 2 diabetes has demonstrated favourable effects in prostate cancer (PCa) across a range of studies evaluating PCa patient outcomes amongst metformin users. This review by Dr Gunter et al highlights the potential of metformin to be repurposed as an anticancer agent, warranting further investigation of metformin in the setting of PCa.

Gene expression based inference of cancer drug sensitivity

Anja Rockstroh — 2022-09-27T00:00:00Z

In this study, we introduce Precily, a predictive modeling approach to infer treatment response in cancers using gene expression data. We assessed the predictability of treatment outcomes and demonstrated the applicability of our approach on patient drug response data.

Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation

Anja Rockstroh — 2022-01-25T00:00:00Z

Our research by Dr Tang et al associates NRP1 expression with shorter relapse- and metastasis-free survival, which implicates NRP1 with the aggressive phenotype of claudin-low breast cancer and offers a novel targeted therapeutic approach to this poor prognosis subtype.

PA Giving Day PA Prostate Team Fundraising a Great Success

Lisa Philp — 2021-09-06T23:12:18Z

This PA Giving Day, the APCRC-Q raised over $13,800 thanks to the efforts of our wonderful PA Prostate team and the PA Research Foundation. Our Prostate team kicked off the day with a bake sale which was a huge success. Together the efforts of the PA Hospital community, the PA Giving Day collectively raised over $605,000 to fund patient support initiatives, medical research, staff education and specialist equipment at the PA Hospital Campus. A huge thanks to everyone for their support with donations on the day quadrupled, thanks to matching donors.

Preventing the Respiratory Failure Causing COVID-19 Mortality, Potent New Drugs Targeting Hyperinflammation

Lisa Philp — 2021-08-12T04:58:19Z

Targeting the Dysregulation of Adiponectin as a Novel Prostate Cancer Therapy

Lisa Philp — 2021-08-12T04:48:30Z

Leptin antagonism inhibits prostate cancer xenograft growth and progression

Anja Rockstroh — 2021-04-29T08:00:00Z

Our study by Dr Philp et al reveals the world-first preclinical evidence that demonstrates marked efficacy of targeted leptin-signalling blockade, using Allo-aca, a potent, specific, and safe LEPR peptide antagonist. This highlights LEPR blockade in combination with androgen axis inhibition as a promising new therapeutic strategy vital in advanced PCa treatment.

Nataly Stylianou